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Available online 28 November 20155-Aminolevulinic acid (5-ALA) is a naturally occurring amino acid and precursor of heme and protoporphyrin IX
(PpIX). Exogenously administrated 5-ALA increases the accumulation of PpIX in tumor cells speciﬁcally due to
the compromised metabolism of 5-ALA to heme in mitochondria. PpIX emits red ﬂuorescence by the irradiation
of blue light and the formation of reactive oxygen species and singlet oxygen. Thus, performing a photodynamic di-
agnosis (PDD) and photodynamic therapy (PDT) using 5-ALA have given rise to a new strategy for tumor diagnosis
and therapy. In addition to the ﬁeld of tumor therapy, 5-ALA has been implicated in the treatment of inﬂammatory
disease, autoimmune disease and transplantation due to the anti-inﬂammation and immunoregulation properties
that are elicited with the expression of heme oxygenase (HO)-1, an inducible enzyme that catalyzes the rate-
limiting step in the oxidative degradationof heme to free iron, biliverdin and carbonmonoxide (CO), in combination
with sodium ferrous citrate (SFC), because an inhibitor of HO-1 abolishes the effects of 5-ALA. Furthermore, NF-E2-
related factor 2 (Nrf2), mitogen-activated protein kinase (MAPK), and heme are involved in the HO-1 expression.
Biliverdin and CO are also known to have anti-apoptotic, anti-inﬂammatory and immunoregulatory functions.
We herein review the current use of 5-ALA in inﬂammatory diseases, transplantationmedicine, and tumor therapy.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Nrf21. Introduction
5-Aminolevulinic acid (5-ALA) as described in detail in Table 1,
a naturally occurring amino acid, is synthesized through the condensa-
tion of glycine and succinyl-CoA by the catalytic effect of 5-ALA
synthase. In the cytosol, 5-ALA sequentially generates porphobilinogen,
hydroxymethylbilane, uroporphyrinogen III and ﬁnally copropor-
phyrinogen III. In the mitochondrion, coproporphyrinogen III is
metabolized to coproporphyrinogen III, protoporphyrinogen IX andpro-
toporphyrin IX, intowhich iron is inserted via a ferrochelatase-catalyzed
reaction, the latter resulting in the formation of heme [1–3]. 5-ALA is uti-
lized as a precursor of a photosensitizer for performing a photodynamic
diagnosis (PDD) and photodynamic therapy (PDT) to conﬁrm and kill
tumor cells [1,4]. Due to the substance's short half-life, the toxicity of
5-ALA is very low. The half-life of 5-ALA by 5-ALA administration
(20 mg/kg) is 55.2 min in human (our unpublished data), 45 min in
human (100 mg) [5], and 40.7 min in dog (7.29 mg/kg) [6]. As a result,
clinically relevant photosensitivity is negligible. In addition to theImmunology, National Research
, Setagaya-ku, Tokyo 157-8535,
. This is an open access article underutilization of PDD and PDT, 5-ALA has been undertaken to treat inﬂam-
matory disease, autoimmune disease and transplantation due to the
anti-inﬂammation and immunoregulation properties by upregulation
of hemeoxygenase (HO)-1 expression and release of hememetabolites.
2. Tumor therapy
2.1. Tumor cells and PpIX accumulation
Several factors, although the preferential mechanisms are unknown,
have been demonstrated to be involved in the accumulation of PpIX.
The expression level of peptide transporter 1 (PEPT1)/solute carrier
family 15 member 1 (SLC15A1), ATP-binding cassette sub-family G
member 2 (ABCG2) [7,8], SLC6A6 and SLC6A13 [9], which are responsi-
ble for the import of 5-ALA and export of PpIX, and the activity of
ferrochelatase [10,11] are key regulators of PpIX accumulation. Heme
biosynthesis and the ironmetabolism are also involved in PpIX accumu-
lation. Inner mitochondrial membrane proteins (mitoferrin-1, which
is mainly expressed in erythroid cells, and mitoferrin-2, which is
expressed in various cells) are dependent on the transport of iron into
mitochondria [12]. In the last step of heme biosynthesis, frataxin-
mediated iron delivery to ferrochelatase occurs [13]. Ohgari et al.
showed that the overexpression of mitoferrin-2 decreased PpIXthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Property of 5-aminolevulinic acid hydrochloride.
Structural formula C5H9NO3・HCl
Synonym 5-Amino-4-oxopentanoic acid hydrochloride
CAS no. No. 5451–09-2
Molecular weight 167.6
Color White to off-white
Melting point (°C) 144–147 (degradation)
pH (1 mol/L) 1.7
Water solubility Very soluble
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overexpressing cells had decreased the amount of intracellular PpIX
accumulation [15].
2.2. 5-ALA and PDD
As shown in Fig. 1 (left), 5-ALA is incorporated into cells by exogenous
administration and converted into PpIX, which is a ﬂuorescent and has
photoactivity. Speciﬁc irradiation at 375–475 nm wavelength excites
PpIX and generates red ﬂuorescence. PpIX has another property, which
is its accumulation in tumor cells, and augmented red ﬂuorescence re-
sults in the identiﬁcation of tumor cells. Its emission of red ﬂuorescence
and accumulation in tumor cells are fundamental for PDD [16–18].
2.3. 5-ALA and PDT
PDT has become one of the standard procedures of cancer therapy,
which is achieved by the generation of reactive oxygen species (ROS)
and singlet oxygen by porphyrin derivatives through the irradiation of
visible light [19–21]. PpIX metabolized from 5-ALA is one of the most
efﬁcacious photosensitizing agents for PDT [22,23]. The tumor-
preferential accumulation of PpIX allows tumor therapy by 5-ALA-
mediated PDT (Fig. 1 left).Fig. 1. PDD, PDT and anti-inﬂammatory/immunoregulatory structure and property of 5-ALA. In
by ferrochelatase. In contrast, less ferrochelatase expression in cancer cell gives rise to accumula
catalyzes heme to CO, Fe and biliverdin.3. 5-ALA and anti-inﬂammatory and immunoregulatory properties
3.1. HO-1
5-ALA has been demonstrated to induce the upregulation of heme
oxygenase (HO)-1 mRNA levels [24,25]. In heme catabolism, HO func-
tions as a rate-limiting enzyme. As shown in Fig. 1 (right), HO catalyzes
heme degradation, thereby producing biliverdin, carbon monoxide
(CO) and iron. HO-1 is the inducible isoform of HO [26] and the expres-
sion of HO-1 is induced by a range of stress stimuli [27–34], including
heme [30,35] and other metalloporphyrins [36,37], in a number of cell
types. Endotoxin exposure to mice with HO-1 deﬁciency results in a
higher mortality from endotoxic shock, the upregulation of splenic
proinﬂammatory cytokine secretion and increased hepatocellular
necrosis compared with wild-type mice [38]. A study on individuals
with HO-1-deﬁciency has strengthened the above ﬁnding and HO-1
has been shown to act as an important cytoprotective factor in
counteracting the detrimental increase in oxidative injury and inﬂam-
mation [39]. Similarly, an in vitro study conﬁrmed that there is a
reduction of stress resistance in HO-1-deﬁcient cells [40].3.2. HO-1 and signal transduction pathway
The signaling mechanisms that activate the transcription of HO-1
remain insufﬁciently elucidated. Many studies have focused on the
activation of mitogen-activated protein kinases (MAPKs) related to
cell growth and the stress response. The pathway of p38, c-Jun.
N-terminal kinase (JNK) and extracellular signal regulated kinase
(ERK) appear to participate to some degree in the upregulation of the
HO-1 expression in response to various stimuli [41–43].MAPK signaling
leads to the translocation of nuclear factor erythroid 2-related factor 2
(Nrf2) to thenucleus [43]. Nrf2 is a basic leucine zipper (bZip) transcrip-
tion factor [44]. Under basal conditions, Bach1,which is also a bZip tran-
scription factor [45], forms heterodimers with musculoaponeurotic
ﬁbrosarcoma oncogene homolog K (MafK), and these heterodimersnormal cell, 5-ALA produces PpIX, then heme is produced by aiding in the insertion of iron
tion of PpIX. 5-ALAwith SFC produces heme and upregulates the expression ofHO-1,which
73M. Fujino et al. / International Immunopharmacology 37 (2016) 71–78repress the transcription of HO-1 gene by binding to the sequence of the
Maf recognition element (MARE) in the HO-1 promoter [46].
3.3. HO-1 and Nrf2
In response to various stimuli, Nrf2 translocates to the nucleus,
which is followed by the subsequent induction of the HO-1 expression
[27,47]. Nrf2 heterodimerizes with small Maf proteins (sMaf) in the
induction of HO-1 through binding to MARE [45,46,48–50]. sMaf,
which include MafF, MafG and MafK, possess a characteristic bZip
domain that mediates DNA binding and dimerization with other bZip
proteins such as Nrf2 [51]. Nrf2 resides in the cytosol bound to Keap1,
a known negative regulator of Nrf2, in the cytoplasm [52,53]. Upon
activation, Nrf2 is released from Keap1 and enters the nucleus, where
it heterodimerizes with sMaf and binds to the MARE in the promoters
of various target genes [49,52]. Hemin evokes the nuclear translocation
of Nrf2 and Nrf2-speciﬁc siRNA suppresses the induction of HO-1 by
hemin in human monocytes [54]. Other metalloporphyrins were also
conﬁrmed to cause the nuclear localization of Nrf2 followed by Nrf2-
mediated HO-1 induction [36,37]. Moreover, HO-1 induction by
lipopolysaccharide (LPS) was also inhibited by Nrf2 downregulation
[27].
3.4. Heme
Heme controls the HO-1 expression [30,35,41,54]. The transcription
factor Bach1 heterodimerizes with Maf proteins and binds to MAREs,
thereby repressing MARE-dependent transcription, including the
transcription of HO-1. In contrast, the DNA binding activity of Bach1 is
negatively regulated by heme binding [55]. In the presence of higher
concentrations of heme, increased binding of heme to Bach1 leads to a
conformational change and a decrease in DNA binding activity [55,56].
This derepression permits Nrf2–sMaf and other activating heterodimers
to occupy the MARE regions in the HO-1 promoter, and thus leads to
increased transcription and upregulation of the gene expression.
3.5. CO
HO-1 catalyzes the conversion of heme to CO and biliverdin/
bilirubin with the concurrent release of iron (Fe2+). Exogenously
added CO and biliverdin/bilirubin show a robust effect in antioxidation
and protection against renal ischemia reperfusion injury (IRI) [57]. CO
Exposure to the recipients improved the functions of the renal graft,
the maintenance of internal cellular architecture, less frequent
vacuolization, preservation of foot processes, and an ultrastructural
improvement according to transmission electron microscopy of viable
podocytes in a rat model of transplant-induced IRI [58]. Furthermore,
the inhalation of CO reduced programmed tubular epithelial cell death
and a decline in nitrite/nitrate formation and the expressions of
interleukin (IL)-6, IL-1β, intercellular adhesion molecule (ICAM)-1 and
inducible nitric oxide synthase (iNOS) [58]. In addition, previous reports
indicated that CO inhibited not only acute and chronic allograft rejec-
tion, but also xenograft rejection in the ﬁeld of transplantation
[59–63]. Kidney IRI causes a profound problem that inﬂuences the out-
comeof renal transplantation [64]. Ten to 500 ppmconcentrations of CO
demonstrated both pharmacological and biological effects which
prevented the onset of ischemic injury [62]. CO can confer the beneﬁcial
effects of anti-inﬂammatory and anti-cell death in IRI [65]. In a rat
kidney transplantation model, inhalation of low concentration CO was
shown to protect against cold IRI [66]. On the other hand, a theoretical
risk of impaired O2 delivery to organs and tissues by increasing
carboxyhemoglobin has been reported in the context of endogenous
CO administration [67,68]. Heme degradation through the activity of
HO-1 generates CO during IRI and the administration of CO upregulates
HO-1 expression, with the subsequent suppression of mouse-to-rat
cardiac xenograft rejection [63].3.6. Bilirubin/biliverdin
The treatment of bilirubin improved the mitochondrial integrity,
tubular function, glomerular ﬁltration rate, urine output and renal
vascular resistance in IRI [69]. In renal transplant recipients, CO gas or
biliverdin treatment alone could not recover proteinuria or a decreased
creatinine clearance, whereas the concurrent administration of CO gas
and biliverdin normalize all these parameters [70]. Furthermore, the
extravasation of inﬂammatory inﬁltrates and upregulation of proin-
ﬂammatory mediators in IRI were signiﬁcantly low with combination
treatment compared with untreated controls [70]. Previous reports
assessing the effect of biliverdin/bilirubin and CO in IRI have suggested
that biliverdin/bilirubin and CO presumably have an effect via different
mechanisms according to the results of the above-mentioned report
[70] and because the simultaneous administration of the two com-
pounds showed additive protection [71].
3.7. HO-1 and regulatory dendritic cells (RegDC)
HO-1 has been identiﬁed as a potential regulator of DC maturation
[72,73]. Al-Huseini et al. [74] demonstrated that the treatment of
SnPP-IX, an inhibitor of HO-1, resulted in the mature phenotype of DC
with impaired phagocytic and endocytic capacity and an enhanced
ability to stimulate antigen-speciﬁc T cell proliferation.
4. Application of 5-ALA in inﬂammatory diseases and transplantation
4.1. Cardiomyocyte hypertrophy
Cardiac hypertrophy is a complex inﬂammatory disease that
develops via the dysregulation of various signal transduction pathways
and oxidative stress and excess ROS production and plays a deﬁnitive
role in the pathogenicity of cardiac hypertrophy [75–77]. Using HL-1
cells, a murine cardiomyocyte cell line that maintains phenotypic
characteristics of adult cardiomyocytes [78], and a well-established
in vitro model of oxidant-induced cardiomyocyte hypertrophy [79],
we evaluated the protective effect of 5-ALA/SFC on cardiac hypertrophy
(unpublished data). Numerous studies have indicated that intrinsic
antioxidants, including superoxide dismutase and vitamin E, can remit
hypertrophy through the reduction of ROS generation [77,80,81].
Additionally, simvastatin, a reductase inhibitor, can function as an anti-
oxidant and inhibit hypertrophy via the inhibition of ROS production
[82]. A ubiquitous thiol oxidoreductase thioredoxin has also been
demonstrated to prevent oxidative stress by direct scavenging of ROS
[83]. H2O2 treatment induced planarmorphometry, 3H-leucine incorpo-
ration, and ROS production in HL-1 cells, and the expression of
hypertrophy-related genes, including β-myosin heavy chain (β-MHC),
atrial natriuretic factor (ANF), brain natriuretic peptides (BNP), and
atrial natriuretic peptide (ANP), while 5-ALA/SFC signiﬁcantly reduced
these effects by H2O2. 5-ALA/SFC treatment elevated the expression of
Nrf2 and HO-1 in dose- and time-dependent manners and Nrf2 knock-
down decreased this 5-ALA/SFC-dependent effect. p38, ERK1/2, and
JNK/stress-activated protein kinase (SAPK) were activated in HL-1
cells pretreated with 5-ALA/SFC, which was inhibited by pharmacolog-
ical inhibitors of these kinases. [84].
4.2. Renal IRI
Reperfusion subsequent to ischemia generates ROS, mitochondrial
failure, endothelial dysfunction, and sterile inﬂammation. Thus, IRI is
a complex pathophysiological process involving oxidant damage
and programmed cell death (PCD) that leads to acute renal failure
(ARF). Approximately 50–70% of the mortality occurs in ARF patients
in intensive care who require dialysis and among postoperative
patients, 25–100% of them suffer fromARF. Regarding renal transplanta-
tion, renal IRI may elicit acute posttransplant tubular necrosis [85–88]
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by the activation of enzymes and chemical mediators, such as prosta-
glandins, leukotrienes, lysozymes, phospholipase A2, and ROS, in renal
IRI.
Signiﬁcant cellular damage also induces the activation of macro-
phages and other parenchymal cells and the secretion of numerous
inﬂammatory mediators, such as tumor necrosis factor (TNF)-α and
IL-1β, which subsequently elicits extravasation of neutrophils, macro-
phages, and T lymphocytes to the interstitial space [91–94]. In our pre-
vious study [25], IRI inmice resulted in an exacerbated kidney function,
as exhibited by increased serum levels of creatinine and blood urea
nitrogen (BUN), and a decreased survival rate 24 h after IRI; in contrast,
5-ALA/SFC treatment prevented these events in a dose-dependentman-
ner. Moreover, 5-ALA/SFC treatment prevented tubular vacuolization,
congestion, necrosis, swelling and dilation by IRI. Furthermore, 5-ALA/
SFC treatment inhibited PCD and the accumulation of macrophages in
the kidneys compared with the no 5-ALA/SFC group after IRI. 5-ALA/
SFC also inhibited the rise of thiobarbituric acid reactive substance
(TBARS), a lipid peroxidation marker which is universally utilized to
assess cellular injury as well as oxidative stress, following IRI. In 5-
ALA/SFC-treated mice, CO in the kidney was signiﬁcantly elevated and
ZnPPIX, an inhibitor of HO-1, prevented CO production in the kidney.
In addition, IRI and 5-ALA/SFC treatment increased the HO-1 expression
in the kidney. These results suggested that 5-ALA/SFC can safeguard the
kidneys against IRI by reducing renal cell apoptosis and macrophage
invasion through CO generation.
4.3. Cardiac allograft
Organ transplantation is the optimal treatment for end-stage organ
failure, while allografts are generally rejected by the recipient's immuneFig. 2. Mechanism of HO-1 induction by 5-ALA. 5-ALA induced HO-1 expression through M
observations, treatment with 5-ALA combined with SFC (5-ALA/SFC) induces the phosphory
their effects on post-transcriptional factors, such as Nrf2. In this pathway, 5-ALA/SFC indirec
intracellular levels of heme.Under conditionswith a higher concentration of heme, theHO-1 rep
expression of HO-1. In this pathway, 5-ALA/SFC directly regulated HO-1 expression (modiﬁedsystemattacks. The exploitation of immunosuppressants and the reﬁne-
ment of surgical techniques have led to improvements in the short-term
outcomes of organ transplantation. However, recipients have to remain
on immunosuppressant therapy for their lifetime; hence, there is a risk
of adverse effects that can cause infectious disease and carcinogenesis.
Therefore, novel immunosuppressants with known independent
mechanisms are required. We previously demonstrated [95] that
5-ALA/SFC treatment for the donor (C57BL/10; B10) and recipient
(CBA/N; CBA) of cardiac allograft, but not 5-ALA or SFC alone, induced
permanent acceptance of fully major histocompatibility complex
(MHC)-mismatched cardiac allografts in a dose-dependent manner.
5-ALA/SFC prevented graft structure, CD8+ T cell inﬁltration and
obliterative vasculopathy, a characteristic of chronic graft rejection.
Responder cells from 5-ALA/SFC-treated mice exhibited a reduced
mixed lymphocyte reaction (MLR). A ﬂow-cytometric (FCM) analysis
of graft-inﬁltrating lymphocyte (GIL) and splenocytes from the recipi-
ents demonstrated that 5-ALA/SFC treatment increased the population
of CD4+CD25+FoxP3+ Tregs. The expression of immunomodulatory
cytokines (HO-1, transforming growth factor (TGF)-β, IL-10) and tran-
script molecule transcription (Foxp3) in the grafts were upregulated
by 5-ALA/SFC treatment. Furthermore, a GIL analysis showed that
5-ALA/SFC treatment increased the number of RegDCs in the graft and
related mRNA expression (indoleamine 2,3-dioxygenase (IDO), iNOS
andHO-1). The secondary CBAallograft recipients treatedwith adoptive
transfer of splenocytes from 5-ALA/SFC-treated primary CBA recipients
exhibited a signiﬁcantly prolonged survival of the B10 hearts, but not
BALB/c (third party) hearts. Furthermore, DCs from 5-ALA/SFC-treated
recipient mice demonstrated a decline in the MLR, number of B10
stimulator cells and number of CBA responder cells as regulatory cells.
The immunomodulatory effects of 5-ALA/SFC were abrogated by a
HO-1 inhibitor.APK signal transduction and synthesized to heme. In the HO-1 induction based on our
lation of ERK and p38 MAPK. These activated MAPKs lead to HO-1 expression through
tly regulated HO-1 expression. On the other hand, exposure to 5-ALA/SFC increases the
ressor, Bach1, is inactivated bydirect binding to heme to Bach1,which allows for increased
from Ref. [103]).
Table 2
Pleiotropic effects of ALA on immune-related diseases and transplantation.
Diseases Main results Articles
Cardiomyocyte hypertrophy 5-ALA + SFC alleviate the H2O2-induced hypertrophy-like symptoms in HL2 cardiomyocyte cell line. Zhao et al. 2015 [84]
Renal ischemia reperfusion injury 5-ALA + SFC alleviate renal injury induced by Ischemia reperfusion through CO generation. Hou et al. 2013 [25]
Heart transplantation In cardiac allograft transplantation model, administration of 5-ALA + SFC to donor and recipient
induces permanent acceptance of the graft. The number of regulatory T cells and regulatory dendritic
cells is increased in this model.
Hou et al. 2014 [95]
- HO-1 protein is induced by 5-ALA + SFC administration to macrophage cell line RAW264 via MAPK
phosphorylation and negative regulation of Bach1.
Nishio et al. 2014 [103]
Graft versus host disease/systemic sclerosis In graft versus host disease/systemic sclerosis model (allogenic bone marrow transplantation to the
immunodeﬁcient mice), 5-ALA + SFC ameliorate skin ﬁbrosis, vascular damage, and macrophage
inﬁltration.
Unpublished
Chronic cyclosporine nephropathy 5-ALA + SFC ameliorate cyclosporine A-induced inﬂammation and ﬁbrosis in kidneys of mice. Unpublished
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Alloreactive immune reactions from donor-derived immune cells to
host cell populations induce graft-versus-host disease (GvHD). Trans-
plantation of bone marrow and splenocytes from B10.D2 mice into
BALB/c Rag2−/− recipients is a well-known animal model for human
sclerodermatous chronic GvHD and SSc, which exhibit many clinical
similarities [96]. Histologically, the invasion of mononuclear cells into
the dermis concomitant with an increase in collagen synthesis has
been shown in the early stages of SSc and sclerodermatous chronic
GvHD in mice. In our experiment (unpublished data), treatment of
5-ALA/SFC ameliorated the decline in body weight in the murine
sclerodermatous chronic GvHD model and inhibited the severity and
ﬁbrosis and vascular damage in SSc. Furthermore, treatment of 5-ALA/
SFC also prevented collagen-1 overproduction and the inﬁltration of
CD4+T cells andmacrophages into the skin.Moreover, 5-ALA/SFC treat-
ment diminished the expression of mRNA related inﬂammation and
SSc, including TGF-β, iNOS, interferon (IFN)-γ, TNF-α, IL-6, and RANTES
in the skin.Fig. 3. Hypothetical mechanism of 5-ALA-induced multiple effects. 5-ALA/SFC-incorporated
immune regulatory response.4.5. Chronic cyclosporine nephropathy
Cyclosporine (CsA), an inhibitor of calcineurin, was clinically
approved for use in the early 1980s and has revolutionized transplant
medicine. CsA remains an attractive agent for immunosuppression in
various solid organ transplantations. Despite the remarkable improve-
ment in the rejection rates and graft survival, side effects were found
with the early stage of its use. One of themost serious adverse reactions
is nephrotoxicity due to long-term CsA usage. In mice, the administra-
tion of CsA (30mg/kg/day s.c.) with a low salt diet for 4weeks increases
the BUN and serum creatinine levels and decreases the glomerular
ﬁltration rate (GFR) along with morphological changes, resulting in
renal endothelial dysfunction, arteriolar injury, tubular atrophy and
interstitial ﬁbrosis. Bing et al. [97] demonstrated that nephropathy
induced by CsA appears to involve the activation of nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase, renin angiotensin
system, and the overexpression of TGF-β and IL-6 in endothelial cells.
In our experiment, treatment with 5-ALA/SFC signiﬁcantly reduced
progressive inﬂammation and ﬁbrosis in the kidney. The elevatedcell induce HO-1 expression and exert the anti-oxidative and/or anti-inﬂammatory and
76 M. Fujino et al. / International Immunopharmacology 37 (2016) 71–78expression of HO-1 in the mouse kidney was shown in 5-ALA/
SFC administration. Further, 5-ALA/SFC was shown to attenuate
tubulointerstitial ﬁbrosis and renal apoptosis in chronic cyclosporine
nephropathy (unpublished data).5. HO-1 expression by 5-ALA/SFC in macrophages
Activated macrophages play an important role in inﬂammatory
diseases including IRI, CsA-nephropathy and SSc. The early inﬁltration
of macrophages plays an important pathogenic role in these diseases,
presumably by the release of proinﬂammatory cytokines and
chemokines [93]. Furthermore, macrophages have been known to be
responsible for allograft rejection and GvHD development [98,99].
The production of inﬂammatory cytokines, including IL-1, IL-18 and
TNF-α, as well as ROS and eicosanoids by macrophages may promote
donor allograft rejection [100,101], while the acquisition of the regula-
tory phenotype in macrophages may attenuate the alloimmune
response [101]. Additionally, we found that DCs treated with 5-ALA/
SFC showed a regulatory phenotype (unpublished data). Furthermore,
Sierra-Filardi et al. [102] demonstrated that HO-1 is important for
the anti-inﬂammatory activities of M2 macrophages. Therefore, we
performed an experiment to determine the effect and signal trans-
duction of 5-ALA/SFC in macrophages with a particular focus on
the expression of HO-1 [103]. As shown in Fig. 2, the combination of
5-ALA/SFC signiﬁcantly upregulated the HO-1 expression compared
with 5-ALA or SFC alone in a dose- and time-dependent fashion. The
ERK and p38 MAPK signaling pathways were upregulated by 5-ALA/
SFC and pharmacological inhibitors of these pathways inhibited the
upregulated HO-1 expression by 5-ALA/SFC. 5-ALA/SFC induced the
translocation of Nrf2 from the cytosol to the nucleus, and Nrf2 knock-
down prevented the HO-1 expression by 5-ALA/SFC. 5-ALA/SFC
increased the intracellular heme and induced the binding of heme to
Bach1. Bach1 knockdown upregulated the HO-1 expression. These
data suggested that HO-1 expression by 5-ALA/SFC in macrophages is
one of the key factors in the anti-inﬂammatory effect of 5-ALA/SFC
treatment.6. Conclusion
5-ALA clearly exerts immunological effects that may potentially be
used to alter the immune responses in autoimmune pathologies,
allografting and GvHD (Table 2). Although the impact of 5-ALA treat-
ment in cancer has been well characterized, the use of 5-ALA for both
immunological diseases and allografting requires further investigation
(Fig. 3). Speciﬁcally, whether or not 5-ALA can be administered in
high enough doses to exert an immunosuppressive effect remains
unclear, however, this is an interesting new treatment option and
further research in the area should be encouraged. Taken together,
these results have important implications for the potential use of
5-ALA/SFC in the treatment of sclerodermatous chronic GvHD and SSc
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